Literature DB >> 23735602

Diagnostic value of bladder tumor fibronectin in patients with bladder tumor: a systematic review with meta-analysis.

Xiaorong Yang1, Huang Huang, Zongyue Zeng, Liuyang Zhao, Ping Hu, Dali He, Xi Tang, Zhaofang Zeng.   

Abstract

OBJECTIVES: Bladder tumor fibronectin (BTF) has been related as a promising biomarker for the early diagnosis of bladder tumor. The meta-analysis was used to establish the diagnostic value of bladder tumor fibronectin in diagnosing bladder tumor.
METHODS: Relevant literatures evaluating the value of BTF in the diagnosis of bladder tumor were searched in PubMed, Embase, China National Knowledge Infrastructure (CNKI), Technology of Chongqing (VIP), and Wan Fang Data. Summary estimates were used to evaluate the value of BTF in the diagnosis of bladder tumor by using the Meta-DiSc and STATA 11.0 statistical software.
RESULTS: The meta-analysis included 5 studies (649 patients, 291 controls). The summary estimates revealed that the pooled sensitivity was 81% (95% confidence interval [CI]: 74%-85.1%) and specificity was 80% (95%CI 74%-84%). In addition, the area under the summary ROC curve (AUC) was 0.86 (95%CI 0.82-0.89).
CONCLUSION: BTF is a potential marker for the diagnosis of bladder tumor, and more prospective studies are needed in the future.
Copyright © 2013 The Canadian Society of Clinical Chemists. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  AUC; BTF; Bladder tumor; Bladder tumor fibronectin; CI; DOR; Diagnosis; Meta-analysis; NLR; PLR; QUADAS; SROC; TUR; area under the summary ROC curve; bladder tumor fibronectin; confidence interval; diagnostic odds ratio; negative likelihood ratio; positive likelihood ratio; quality assessment of diagnostic accuracy studies; summary receiver operator characteristic; transurethral resection

Mesh:

Substances:

Year:  2013        PMID: 23735602     DOI: 10.1016/j.clinbiochem.2013.05.064

Source DB:  PubMed          Journal:  Clin Biochem        ISSN: 0009-9120            Impact factor:   3.281


  4 in total

1.  Urinary oncofetal ED-A fibronectin correlates with poor prognosis in patients with bladder cancer.

Authors:  Shanna A Arnold; Holli A Loomans; Tatiana Ketova; Claudia D Andl; Peter E Clark; Andries Zijlstra
Journal:  Clin Exp Metastasis       Date:  2015-10-11       Impact factor: 5.150

Review 2.  Serum microRNA-21 as a diagnostic marker for lung carcinoma: a systematic review and meta-analysis.

Authors:  Xiaorong Yang; Yanan Guo; Yane Du; Jinmei Yang; Shichao Li; Shengnan Liu; Ke Li; Dechun Zhang
Journal:  PLoS One       Date:  2014-05-27       Impact factor: 3.240

3.  CIP2A mediates fibronectin-induced bladder cancer cell proliferation by stabilizing β-catenin.

Authors:  Fengbin Gao; Tianyuan Xu; Xianjin Wang; Shan Zhong; Shanwen Chen; Minguang Zhang; Xiaohua Zhang; Yifan Shen; Xiaojing Wang; Chen Xu; Zhoujun Shen
Journal:  J Exp Clin Cancer Res       Date:  2017-05-18

4.  Fibronectin urothelial gene expression as a new reliable biomarker for early detection of local toxicity secondary to adjuvant intravesical therapy for non-muscle invasive bladder cancer.

Authors:  Fabrizio Di Maida; Cristina Scalici Gesolfo; Riccardo Tellini; Andrea Mari; Chiara Sanfilippo; Luca Lambertini; Antonio Andrea Grosso; Marco Carini; Andrea Minervini; Vincenzo Serretta
Journal:  Ther Adv Urol       Date:  2021-02-27
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.